A detailed history of Massachusetts Financial Services CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 7,095 shares of BGNE stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,095
Previous 8,614 17.63%
Holding current value
$1.61 Million
Previous $1.95 Million 17.62%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 29, 2025

SELL
N/A
-1,519 Reduced 17.63%
7,095 $1.61 Million
Q2 2025

Aug 08, 2025

SELL
N/A
-7,005 Reduced 44.85%
8,614 $1.95 Million
Q1 2025

May 02, 2025

SELL
$175.1 - $226.71 $2.15 Million - $2.79 Million
-12,304 Reduced 44.06%
15,619 $3.54 Million
Q4 2024

Feb 12, 2025

BUY
$174.72 - $246.04 $2.8 Million - $3.95 Million
16,049 Added 135.16%
27,923 $5.16 Million
Q3 2024

Nov 12, 2024

BUY
$143.93 - $224.51 $1.71 Million - $2.67 Million
11,874 New
11,874 $2.67 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.